Patents by Inventor Jenna BAILEY

Jenna BAILEY has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1 (ROR1)
    Publication number: 20250242020
    Abstract: Provided are receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, in particular, to human antibodies specific for ROR1, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for ROR1. The disclosure further relates to genetically engineered cells, containing such ROR1-binding proteins and receptors, and related methods and uses thereof in adoptive cell therapy.
    Type: Application
    Filed: March 11, 2025
    Publication date: July 31, 2025
    Applicant: Juno Therapeutics, Inc.
    Inventors: Andreia COSTA, Rupesh AMIN, Jenna BAILEY, Samriti BEDI, Brian BELMONT, Aye CHEN, Stephen Jacob GOLDFLESS, Eric JEFFERY, Yue JIANG, Yeonjoo OH, Madeline WILLIAMS, Collin HAUSKINS, Catherine SIERRA
  • Antibodies and chimeric antigen receptors specific for receptor tyrosine kinase like orphan receptor 1 (ROR1)
    Patent number: 12268741
    Abstract: Provided are receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, in particular, to human antibodies specific for ROR1, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for ROR1. The disclosure further relates to genetically engineered cells, containing such ROR1-binding proteins and receptors, and related methods and uses thereof in adoptive cell therapy.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: April 8, 2025
    Assignee: Juno Therapeutics, Inc.
    Inventors: Andreia Costa, Rupesh Amin, Jenna Bailey, Samriti Bedi, Brian Belmont, Aye Chen, Stephen Jacob Goldfless, Eric Jeffery, Yue Jiang, Yeonjoo Oh, Madeline Williams, Collin Hauskins, Catherine Sierra
  • ANTIBODIES AND CHIMERIC ANTIGEN RECEPTORS SPECIFIC FOR RECEPTOR TYROSINE KINASE LIKE ORPHAN RECEPTOR 1 (ROR1)
    Publication number: 20220096651
    Abstract: Provided are receptor tyrosine kinase-like orphan receptor 1 (ROR1)-binding molecules, in particular, to human antibodies specific for ROR1, including antibody fragments. The present disclosure further relates to recombinant receptors, including chimeric antigen receptors (CARs) that contain such antibodies or fragments, and polynucleotides that encode the antibodies, antigen-binding fragments or receptors specific for ROR1. The disclosure further relates to genetically engineered cells, containing such ROR1-binding proteins and receptors, and related methods and uses thereof in adoptive cell therapy.
    Type: Application
    Filed: January 28, 2020
    Publication date: March 31, 2022
    Applicant: Juno Therapeutics, Inc.
    Inventors: Andreia COSTA, Rupesh AMIN, Jenna BAILEY, Samriti BEDI, Brian BELMONT, Aye CHEN, Stephen Jacob GOLDFLESS, Eric JEFFERY, Yue JIANG, Yeonjoo OH, Madeline WILLIAMS, Collin HAUSKINS, Catherine SIERRA